Search

Your search keyword '"Stadtmauer, E"' showing total 395 results

Search Constraints

Start Over You searched for: Author "Stadtmauer, E" Remove constraint Author: "Stadtmauer, E"
395 results on '"Stadtmauer, E"'

Search Results

1. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

2. P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

4. Third consensus on medical treatment of metastatic breast cancer

8. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience

16. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

18. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

19. Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study

22. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

23. Predictors of long‐term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma.

25. Second consensus on medical treatment of metastatic breast cancer

38. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)

42. Treatment of PTLD with Rituximab or Chemotherapy

47. PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

48. Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells.

49. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

50. Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cells.

Catalog

Books, media, physical & digital resources